MediWound to Announce Q1 2024 Financial Results

MediWound Ltd., a leader in advanced enzymatic treatments for tissue repair, has announced that it will release its financial results for the first quarter of 2024 on May 29, 2024. Following this announcement, the company's management team will hold a conference call and webcast at 8:30 am Eastern Time to discuss the financial outcomes, share corporate updates, and respond to questions from participants.

The conference call can be accessed via different dial-in numbers provided for toll-free, Israeli, and international participants. A webcast link will also be available for those who prefer to join online. Participants are advised to dial in at least five minutes before the call begins. Additionally, an archived version of the webcast will be available on the MediWound website's Investors section for future replay.

MediWound specializes in next-generation enzymatic therapeutics aimed at non-surgical tissue repair. The company is dedicated to developing, manufacturing, and commercializing biologics that enhance current medical standards, improve patient outcomes, and reduce both costs and the need for surgeries. One of their flagship products, NexoBrid®, is an orphan biologic approved by the FDA and EMA for the removal of eschar in deep partial-thickness and full-thickness thermal burns. This product significantly minimizes the need for surgical interventions.

Building on the same biotherapeutic enzymatic platform, MediWound has developed a robust research and development pipeline. Their leading drug in development, EscharEx®, is poised to enter Phase III clinical trials. EscharEx® is designed for the debridement of chronic wounds and presents potential advantages over the current dominant product in a market valued at over $360 million. This drug offers the possibility of expanding the market and providing more effective treatment options for patients with chronic wounds.